June 14, 2012 3:09 pm by Stephanie Baum | 0 Comments
Venture capital firm Third Rock Ventures has launched a drug development startup to treat genetic blood disorders, with sickle-cell anemia as its lead program target, providing $40.7 million in series ...
Read more
